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Introduction
Pseudomonas aeruginosa is a ubiquitous opportun-
istic Gram-negative non fermentative bacterium of 
clinical significance and preferentially causes severe 
infections in patients with diseases including cancer, 
diabetes, cystic fibrosis, deliberate immunosuppression, 
and major surgery (Osman et al., 2010). The bacterium 
can colonize implanted devices, catheters, heart valves, 
ventilators or dental implants resulting in device-asso-
ciated hospital acquired infections which are of major 
concern globally (El-Kholy et al., 2012). P. aeruginosa is 
associated with different types of infections which cause 
morbidity and mortality (Driscoll et al., 2007; Suárez 
et al., 2010). The high prevalence of P. aeruginosa in 
developing countries and resource-limited parts of the 
world as well as other parts of the world owes much to 
its battery of secreted virulence factors as well as to its 
high resistance to antimicrobial and var ious chemical 
agents (Van Delden and Iglewski, 1998). 
Much evidence on its prominence and emergence 
as a life threatening pathogen is attributed to its high 
intrinsic and acquired resistance to diverse classes of 
antimicrobial agents including antipseudomonal agents 
(Wolter et al., 2009). The resistance rates of P. aeruginosa 
are escalating globally posing a serious public health 
threat (Jones et al., 2003). P. aeruginosa is charac terized 
by increased resistance to antipseudomonal agents 
(Strateva et al., 2007). In vitro sensitivity tests are used 
as a guide for appropriate antimicrobial therapy prior 
to antibiotic treatments. 
Geographical variations and differences in the resis-
tance rates of P. aeruginosa usually correlate with the 
prescription patterns of antimicrobial agents prescrib-
ing habits, overuse of antimicrobial agents in different 
parts of the world, and the selective pressure of certain 
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A b s t r a c t
Pseudomonas aeruginosa is a leading human pathogen that causes serious infections at various tissues and organs leading to life threaten-
ing health problems and possible deadly outcomes. Resistance patterns vary widely whether it is from hospitals or community acquired 
infections. Reporting resistance profiles to a certain antibiotics provide valuable information in a given setting, but may be extrapolated 
outside the sampling location. In the present study, P. aeruginosa isolates were screened to determine their susceptibilities against anti-
pseudomonal antimicrobial agents and possible existing mechanisms of resistance were determined. Eighty-six isolates of P. aeruginosa 
were recovered. Isolates representing different resistance profiles were screened for the existence of three different resistance mechanisms 
including drug inactivation due to metallo-β-lactamases, drug impermeability by outer membrane proteins and drug efflux. All tested iso-
lates showed uniform susceptibility (100%, n = 86/86) to piperacillin, meropenem, amikacin, and polymyxin B. A single isolate was found 
to be imipenem resistant (99%, n = 85/86). The possible mechanisms of resistance of P. aeruginosa to imipenem involve active drug efflux 
pumps, outer membrane impermeability as well as drug inactivating enzymes. These findings demonstrate the fundamental importance 
of the in vitro susceptibility testing of antibiotics prior to antipseudomonal therapy and highlight the need for a continuous antimicrobial 
resistance surveillance programs to monitor the changing resistance patterns so that clinicians and health care officials are updated as to 
the most effective therapeutic agents to combat the serious outcomes of P. aeruginosa infections.
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anti biotics (El Zowalaty et al., 2015). The literature is 
rich in surveillance studies from all over the world 
reporting varying resistance rates among P. aeruginosa 
against different antimicrobial agent. Recently, studies 
have focused on the decreased susceptibility of P. aeru­
ginosa to currently used antipseudomonal agents, 
including β-lactams, aminoglycosides, and fluoroqui-
nolones (Al-Tawfiq, 2007) since resistance of P. aeru­
ginosa to carbapenems, piperacillin, and other highly 
active antibiotics has emerged and is increasing which 
makes treatment of P. aeruginosa infections trouble-
some (Strateva et al., 2007).
Recently, resistance rates of P. aeruginosa clinical 
isolates recovered from patients admitted to Zagazig 
University hospitals in Egypt against different classes of 
antimicrobial agents were reported (El Zowalaty, 2012). 
The current study further examined the susceptibili-
ties and possible resistance mechanisms of P. aeruginosa 
isolates collected from hospitalized patients against 
selected antipseudomonal agents that are available in 
the Egyptian pharmaceutical market and are frequently 
prescribed to patients. 
Experimental
Materials and Methods
Study site. The specimens were collected from Zaga-
zig university-affiliated hospitals as well as outpatient 
clinics. Meropenem, polymyxin B, and piperacillin have 
not been previously prescribed while imipenem was 
sometimes prescribed (depending on socioeconomic 
factors). Other antimicrobial agents including ceftazi-
dime, ceftriaxone, ciprofloxacin, amikacin, gentamicin, 
cefotaxime, are first line frequently prescribed antibio-
tics to all patients regardless of the pathogen antimicro-
bial sensitivity profile.
Ethics statement. Ethical approval to perform the 
study was obtained from all patients. Consent was 
obtained from each patient included in the study as well 
as from Zagazig University hospital and the Depart-
ment of Microbiology ethical committee. All samples 
were de-identified and analyzed anonymously. 
Bacterial isolates. Eighty-six non-repeat clinical 
isolates of P. aeruginosa were collected from hospital-
ized patients with urinary tract infections, respiratory 
tract infections, cystic fibrosis, wounds, ear infections, 
and septicaemia. All patients were under antimicrobial 
clinical protocol treatment consisting of cefotaxime, 
ceftazidime, ceftriaxone, gentamicin, or ciprofloxa-
cin. Specimens were collected as urine, purulent dis-
charge or sputum according to the type of infection. 
The isolates were collected, identified, and confirmed 
to be P. aeruginosa by routine conventional biochemi-
cal tests. P. aeruginosa isolates were cultured aerobically 
in Muller-Hinton broth for 16–24 hours at 37°C. The 
isolates were Gram stained, and first inoculated into 
brain heart infusion medium, then cultured on cetrim-
ide agar. Gram-negative bacilli were further confirmed 
to be P. aeruginosa using conventional biochemical 
characteristics. The isolates were further tested for the 
presence of cytochrome oxidase enzyme using oxidase 
reagent (bioMérieux, Marcy-l’Etoile, France), oxida tive 
fermentation, and ability to grow at 42°C. All isolates 
were stored in Mueller-Hinton broth (Difco Laborato-
ries, Maryland, USA) with 30% glycerol (Merck, Darm-
stadt, Germany) at –20°C until additional tests were 
performed as described below. The standard laboratory 
reference strain P. aeruginosa ATCC 90271 (Manassas, 
VA, USA) was used as control in this study.
Antibiotics. The following antibiotics were obtained 
from the corresponding supplier: amikacin (Bristol 
Myers Squibb, Cairo, Egypt), imipenem (Merck Sharp 
and Dohme, Hertfordshire, U.K.), meropenem (Astra-
Zeneca, Cheshire, U.K.), ticarcillin and piperacillin, 
(Sigma-Aldrich, Saint Louis, Missouri, USA), and poly-
myxin B (Novo Industry A/S, Copenhagen, Denmark).
Antimicrobial susceptibility testing. The mini-
mum inhibitory concentrations (MICs) (μg/ml) of 
different antibiotics were determined on Muller-
Hinton agar dilution method as previously described 
(Andrews, 2001) and in accordance with the guide-
lines of the Clinical and Laboratory Standards Institute 
(CLSI, 2015) .
Detection of metallo-β-lactamases (MβLs). Detec-
tion of MβLs in imipenem resistant P. aeruginosa iso-
late was performed using EDTA-disc diffusion synergy 
test as described previously (Jesudason et al., 2005). An 
overnight broth culture of the carbapenem resistant iso-
late was adjusted to 0.5 McFarland opacity standards 
and was used to inoculate plates of Mueller-Hinton 
agar. After drying the plates by incubation at 37°C for 
one to 2 h, a 10 µg imipenem disc (Oxoid Ltd., Basing-
stoke, Hampshire, England) and a blank filter paper 
disc were placed 10 mm apart from edge to edge, 5 µl 
of 0.5 M EDTA disodium. Aqueos solution, prepared 
by dissolving 186.1 g in 1000 ml of distilled water and 
adjusting it to pH 8.0 using NaOH and sterilized by 
autoclaving, was then applied to the blank disc, which 
resulted in a concentration of approximately 750 µg 
EDTA per disc. After overnight incubation, the pres-
ence of an enlarged zone of inhibition was interpreted 
as EDTA synergy positive. P. aeruginosa ATCC 90271 
was used as negative control microorganism. 
β-lactam hydrolysis assays. The β-lactamase activ-
ity was determined by spectrophotometric assay using 
β-lactam antibiotics (ampicillin and imipenem) as 
substrates in the presence and absence of β-lactamase 
inhibitors (clavulanic acid and p­chloromercuriben-
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zoate; p­CMB). The effects of crude β-lactamase extract 
on various β-lactam antibiotics were determined as pre-
viously described (Danel et al., 1999; Ayala et al., 2005). 
Briefly, the hydrolytic activity of crude β-lactamase 
extracts of P. aeruginosa isolates to degrade β-lactam 
antibiotics was assayed using UV spectrophotometry 
at 37°C in the presence of phosphate bufferd saline at 
pH 7.0. The following wavelengths were used: ampicil-
lin, 235 nm; cefotaxime, 260 nm; ceftazidime, 260 nm; 
and imipenem, 299 nm. Inhibition of enzymatic activ-
ity of crude extract was performed using different con-
centrations of clavulanic acid, 2 μg/ml; tazobactam, 
4 µg/ml; oxacillin, 1 μM; EDTA (2 μM and 5 μM); and 
sodium p­chloromercuribenzoate (P­CMB), 1 μM and 
assayed following the incubation of the crude extract 
for 20 minutes at 25°C in presence of the previously 
mentioned concentrations of the inhibitor. Each of the 
crude β-lactamase extracts or cell lysates of isolates, 
at a  fixed volume of 200 μl aliquot of crude extract, 
was mixed with the antibiotic solution at zero time in 
0.1 M phosphate buffer (pH 7.0) at 37°C and the change 
in the concentration was monitored by measuring 
the absorbance at the corresponding wavelength. The 
crude extract or cell lysate was pre-incubated with 
the inhibitor for 20 minutes at 37°C. A control without 
the inhibitor was used. 
Detection of efflux pumps activity. The existence 
of efflux mechanism in P. aeruginosa isolates was deter-
mined by detection of the accumulation of ethidium 
bromide in the presence or absence of efflux inhibitors 
as described previously with modifications (Nishino 
and Yamaguchi, 2004). Overnight cultures were 
adjusted to approximately 105 cfu/µl. Washed cells were 
resuspended in 20 µl of 1 µg/ml ethidium bromide with 
or without either 100 μM dinitrophenol (DNP, Stein-
heim, Germany), 0.4% glucose or 0.1% of toluene and 
were incubated at 37°C for 15 min. Cells were collected 
by centrifugation at 1200 × g for 5 minutes and re-sus-
pended in 10 μl of PBS. Five microliters aliquots of cell 
suspensions were spotted onto the surface of 1% aga-
rose gel and examined over ultraviolet transilluminator. 
Drug accumulation in P. aeruginosa cells was observed 
as bright fluorescence of ethidium bromide. To further 
confirm the presence of efflux system of P. aeruginosa 
resistant isolate, the MICs of antimicrobial agents for 
the resistant isolate were determined in the presence 
and absence of 100 μM of the efflux pump inhibitor 
DNP and dicyclohexylcarbodiimide (DCCD, Stein-
heim, Germany).
Molecular detection of antimicrobial resistance 
determinants. Chromosomal DNA template was extrac- 
 ted and conventional PCR was performed. Resistant 
isolates were screened for resistance genes using sets 
of specific oligonucleotide primers as follows: blaIMP-1 
forward (CTACCGCAGCAGAGTCTT TGC) and 
blaIMP-1 reverse (GAACAACCAGTTTTG CCTTACC) 
(Poirel et al., 2000), blaVIM-1 forward (TCTACA TGAC-
CGCGTCTGTC) and blaVIM-1 reverse (TGTGCTTT-
GACAACGT TCGC) (Poirel et al., 2000), blaOXA-50 for-
ward (AATCCGGCGCTC ATCCATC) and blaOXA-50 
reverse (GGTCGGCGACTGAGGC GG) (Girlich et al., 
2004), blaIBC-2 forward (CGTTCCATACAGAAGCTG) 
and blaIBC-2 reverse (AAGCAGACTTGCCTGA) (Mav-
roidi et al., 2001), mexR forward (AACCAATGAAC-
TACCCCGTG) and mexR reverse (ATCCTCAA-
GCGGTTG CGCGG) (Dubois et al., 2001) were used 
to amplify blaIMP-1, blaVIM-1, blaOXA-50, blaIBC-2, and mexR 
genes, respectively. The isolates were inoculated into 
5 ml of trypticase soy broth and incubated for 16 hours 
at 37°C with shaking. Cells from 1.5 ml of an overnight 
culture were harvested by centrifugation for 10 minu-
tes at 15 000 × g. The supernatant was decanted and 
chromosomal DNA from cell pellets was extracted. 
Whole-cell genomic DNA of P. aeruginosa isolates was 
extracted using a QIAamp DNA Mini Kit (Qiagen, 
Maryland, USA) according to manufacturer’s instruc-
tions with one hour incubation at 56°C using 20 µl 
proteinase K solution. DNA was purified using Qiagen 
DNeasy Mini spin column protocol. DNA was hydra- 
ted in 150 µl of DNA elution solution to increase 
the final DNA concentration in the eluate. Extracted 
DNA was aliquoted, stored at –20°C until use. PCR 
analysis was performed using DNA thermal cycler 
Biometra Tpersonal Combi (Whatman Biometra, 
Goettingen, Germany) in a reaction mixture of 100 μl 
volume containing 10 µl (final concentration of 1 µM 
or 1 picomole per µl) of each upstream primer, 10 µl 
(final concentration of 1 µM or 1  picomole per  µl) 
of each downstream primer, 5 µl (final concentration 
of 250 nanogram) of DNA template, 50 µl PCR Master 
Mix, 2X (containing 50 units/ml Taq DNA polymer-
ase, 400 µM deoxynucleotides triphosphate [dATP, 
dGTP, dCTP, dTTP] and 3 mM MgCl2 and nuclease-
free water was added to complete the volume of the 
reaction to 100 µl. PCR conditions for the amplifica-
tion were as follows: an initial incubation of 10 min at 
37°C and an initial denaturation step at 94°C for 5 min, 
followed by 30  cycles of DNA denaturation at 94°C 
for 1 min, primer annealing at 54°C for 1 min, and 
primer extension at 72°C for 1.5  min. After the last 
cycle, the products were stored at 4°C. The PCR ampli-
fication products were analyzed and revealed using 
2% agarose gel electrophoresis in 1X trisacetate buffer 
(0.04 M Tris-acetate, 0.002 M EDTA [pH 8.5]). Ten 
microlitres of each PCR product were mixed with 2 µl 
of blue/orange 6X loading dye and were subjected to 
electrophoresis for 45 min at 80 V using horizontal 
apparatus. After electrophoresis, the ethidium bro-
mide-stained PCR amplification products were visual-
ized under UV light transilluminator. The size of each 
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PCR products was determined by comparing of PCR 
products with DNA molecular size marker (1 kb/100 bp 
ladder; Promega, WI, USA). 
Electrophoretic separation of outer membrane 
proteins. The outer membrane proteins were analyzed 
using sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE), as previously reported (Laem-
mli, 1970), with 10.7% (wt/vol) acrylamide and 0.3% 
(wt/vol) N, N9-methylenebisacrylamide in the running 
gel. Samples for SDS-PAGE were treated with 2% SDS 
w/v – 5% w/v 2-mercaptoethanol at 100°C for 5 min or 
at 37°C for 10 min, and then subjected to electropho-
resis at a constant current of 25 mA at 4°C. The gel was 
stained using coomassie brilliant blue to visualize the 
protein bands. The size of the proteins was determined 
as compared to size of a protein marker (Bio-Rad pro-
tein ladder).
Results
Antimicrobial susceptibility testing. Antimicrobial 
susceptibility results were interpreted using the CLSI 
breakpoints (CLSI, 2015). It was reported previously 
that P. aeruginosa isolates were highly resistant to com-
monly prescribed antibiotics (El Zowalaty, 2012). The 
resistance rates of P. aeruginosa clinical isolates to one 
or more antimicrobial agents were shown in Table  I. 
The respective MIC90 distributions of different antibi-
otics for 86 isolates of P. aeruginosa were shown. All 
tested isolates of P. aeruginosa were susceptible to the 
antibiotics piperacillin, meropenem, amikacin, and 
polymyxin  B. A single isolate was found resistant to 
imipenem. For other antibiotics tested namely ticar-
cillin, ciprofloxacin, ceftazidime, and gentamicin the 
susceptibility rates were shown in Table  I. P. aerugi­
nosa isolated strains were highly resistant to all other 
antibiotics tested. In addition, all of the 86 clinical iso-
lates of P. aeruginosa were resistant to more than three 
classes and were defined as MDR. The resistance rates 
of P. aeru ginosa isolates to one or more antimicrobial 
agents were shown in Figure 1 and Table II. In total, 
forty-two out of eighty-six isolates were found to be 
resistant to three or more antimicrobial agents and the 
rate of multidrug resistant (MDR) P. aeruginosa isolates 
was 47.1% (El Zowalaty, 2012). 
In order to explore the possible existing antimicro-
bial resistance mechanisms in the as-found MDR 
P. aeru ginosa isolates, the detection of MβLs, spectro-
photometric β-lactamase assays, efflux pump acti vity, 
outer membrane protein profiling, and molecular 
detection of resistance determinants were performed. 
A single isolate was found to be imipenem resistant as 
determined using the disk susceptibility testing and had 
Meropenem 2 2 100  0  0
Imipenem 4 4  98.9  0  1.1
Piperacillin 8 32 100  0  0
Ticarcillin 64 128  80.9  0 19.1
Polymyxin B 2 2 100  0  0
Amikacin 8 8 100  0  0
Ceftriaxone 32 256   0 70.8 29.2
Ceftazidime 8 32  59.5 28.1 12.4
Cefotaxime 64 256   0 43.8 56.2
Gentamicin 128 512  12.3  7.9 79.8
Ciprofloxacin 1 128  60.7  6.7 32.6
Table I
Susceptibility of P. aeruginosa isolates (n = 86) to different
antimicrobial agents classes.
a Percentage of all isolates. MICs were determined and isolates were 














5* 4  4.5
6* 1  1.1
Table II
Profiles of P. aeruginosa antibiotic resistance.
* Forty-two out of 89 (47.1%) isolates were resistant to three or more 
antimicrobials and were defined as MDR.
No. of agents to which
isolates were resistant Frequency Percent
Fig. 1. Effect of crude β-lactamase extracts of P. aeruginosa
isolates on ampicillin concentration in absence
of β-lactamase inhibitors.
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a zone diameter of 10 mm. In presence of EDTA disc, 
the zone diameter of imipenem increased to 21 mm. 
The spectrophotometric β-lactamase assays showed 
a decrease in the concentration of ampicillin due to 
the effect of the crude β-lactamase extract activity 
Figure  I. The crude β-lactamase extract activity was 
not inhibited by clavulanate, tazobactam or oxacillin 
while in presence of p­chloromercuribenzoate (PCMB) 
the crude β-lactamase extract activity was inhibited 
as shown in Figure 2. The crude β-lactamase extract 
activity had no effect on the concentration of cefo - 
ta xime and ceftazidime. 
As shown in Figure 3, the crude β-lactamase extract 
activity of IMP-sensitive isolate (B) had no effect on 
the concentration of imipenem while there was 
a decrease in the concentration of imipenem that might 
be attributed to the effect of the crude β-lactamase 
extract activity of IMP-resistant isolate (C). The crude 
β-lactamase extract activity of IMP-resistant isolate (C) 
was inhibited in presence of either EDTA or P-CMB 
as shown in Figure 4.
Resistance through the efflux pump. It was found 
that IMP-resistant isolate was positive for efflux pump 
activity as shown in Figure 5. The reduction in fluores-
cence intensity was observed in the absence of efflux 
pump inhibitor and in the presence of glucose which 
is an efflux pump energizer. In the presence of efflux 
pump inhibitor or toluene, the latter is a  membrane 
permeabilizer; there was an increase in the fluorescence 
intensity. P. aeruginosa ATCC 90271 was used as nega-
tive control. The effect of efflux pump inhibitors (DNP, 
and DCCD) on the MIC of imipenem resistant isolate 
was determined. The MICs of ticar cillin, imipenem, 
Fig. 4. Effect of crude β-lactamase extract of P. aeruginosa isolate C 
(imipenem resistant) on imipenem concentration in presence
and absence of enzyme inhibitors (EDTA and pCMB).
Fig. 2. Effect of crude β-lactamase extract of P. aeruginosa
(isolate C) on ampicillin concentration in presence and absence
of β-lactamase inhibitors (CLV: clavulanic acid, pCMB:
p­chloromercuribenzoate).
Fig. 3. Effect of crude β-lactamase extracts of P. aeruginosa
isolates (B: imipenem sensitive and C: imipenem resistant)
on imipenem concentration.
Fig. 5. Detection of efflux pump activity using ethidium bromide 
accumulation test showing the effect of efflux pump inhibitor 
(dinitrophenol) and glucose (pump energizer) on the accumula-
tion of ethidium bromide in cells of P. aeruginosa (A) P. aerugi­
nosa ATCC 90271, (B) P. aeruginosa imipenem resistant isolate 
and (C) P. aeruginosa imipenem sensitive isolate. Cells loaded 
with ethidium bromide in presence of glucose (1), cells loaded 
with ethidium bromide in presence dinitrophenol (DNP) (2), cells 
loaded with ethidium bromide in presence toluene (3), and cells 
loaded with ethidium bromide (4).
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meropenem, and norfloxacin in the presence and 
absence of the efflux inhibitors was determined. The 
reduction in MIC of a certain antibiotic with DNP or 
DCCD is indicative of resistance against this antibiotic 
mediated by an efflux system.
The addition of DNP and DCCD enhanced the 
activities of selected antibiotics by lowering the MIC 
as observed in the reduction of MIC. In the presence 
of DNP and DCCD, the largest effect was observed 
with ticarcillin and norfloxacin (a 32-fold decrease 
in MIC) followed by aztreonam (16-fold decrease in 
MIC). An intermediate effect was obtained with mero-
penem (8-fold decrease in MIC). These results empha-
sized the existence of efflux-mediated resistance in the 
tested isolates.
Polymerase chain reaction. The tested isolates car-
ried the mexR gene as was determined using PCR ana-
lysis. In addition, PCR analysis revealed the absence of 
the screened blaIMP-1, blaVIM-1, blaOXA-50, and blaIBC-2 genes 
in the tested isolates; however this does not exclude the 
presence of other resistance determinants. 
Analysis of outer membrane proteins. The outer 
membrane protein profiles of P. aeruginosa isolates 
representing different resistance profiles showed the 
presence of a protein band of approximate weight of 
50 kDa, in addition to several bands of approximate 
weights of 17, 23, 35, 38 and 49 kDa.
Discussion
P. aeruginosa gains specific concern among health 
care officials especially in resource limited settings 
(RLS) and developing countries. There are only few 
recent reports on the antimicrobial resistance of P. aeru­
ginosa isolated from patients in Egypt (Abdel et al., 
2010). The present study reported the in vitro activity 
of antipseudomonal drugs against P. aeru ginosa clinical 
isolates. Antibiotic treatment guidelines recommended 
for P. aeruginosa are not similar due to different resist-
ance profiles among isolates from different sources. 
The current study showed that all tested P. aeru­
ginosa clinical isolates were uniformly susceptible to 
meropenem, piperacillin, imipenem, amikacin, and 
polymyxin B. In this study, antimicrobial susceptibility 
testing of eighty-six clinical isolates of P. aeruginosa was 
performed using the agar dilution method according 
to the guidelines of the CLSI (CLSI, 2015). The MIC50 
and MIC90 were 2 and 2 μg/ml for polymyxin and mero-
penem; 8 and 8 μg/ml for amikacin and 8 and 32 μg/ml 
for piperacillin, respectively.
On the contrary, carbapenem resistance among 
P. aeruginosa have been increasing in other parts of the 
world posing a continuous threat and possible looming 
emergence of highly serious pandrug resistant P. aerugi­
nosa, which may be explained in parts by several fac-
tors including the intensive use of carbapenems which 
enhanced the emergence of carbapenem-resistant iso-
lates (Walsh, 2010). 
It has been reported that extensive use and con-
sumption of carbapenems forced the emergence of 
resistance to these antimicrobial agents (Benčić and 
Baudoin, 2001). This probably will present a particular 
challenge and could results in a major global problem 
since carbapenems are the final choice in the treatment 
of the difficult-to-treat pseudomonal infections and 
they are often the last resort for treating infections due 
to multidrug resistant isolates (Nordmann, 2010). The 
emerging carbapenem resistance will be very danger-
ous and of serious complications resulting in pan drug 
resistant strains leading to increased mortality rates 
(Hong et al., 2015; Liu et al., 2015).
In the present study, the resistance rate to imipenem 
was relatively low and accounted for only 1%. Except 
for a single isolate which was found to be imipenem 
resistant with an MIC of 16 µg/ml, all isolates were 
sensitive to imipenem with MIC of 4 µg/ml, MIC50 
and MIC90 were equal to 4 µg/ml. Contrary to the 
present findings, higher resistance rate to imipenem 
were reported where it was found that 29% and 14.3% 
(Hassan et al., 2010) of P. aeruginosa clinical isolates 
were resistant to imipenem. In another study from 
Egypt, 11.9% out of 261 clinical isolates of P. aeruginosa 
isolated from Zagazig University hospital between 2003 
and 2004 were resistant to imipenem as determined by 
disc diffusion method (El-Behedy et al., 2002).
Contrary to the current study, the overall resistance 
rates of P. aeruginosa to imipenem are on continuous 
increase globally. In a Saudi Arabian hospital between 
1998 and 2003, rates were 2.6% and 5.8%, respectively 
(Al-Tawfiq, 2007). In a study from California, USA, 
the annual imipenem resistance rates against P. aeru­
ginosa isolates increased from 2% in 1996 to 18% in 
1999 (Huang et al., 2002). 
The susceptibility rate to imipenem in clinical iso-
lates of P. aeruginosa in a study in Spain was 89.7% from 
2005 to 2010 (Casal et al., 2012). The susceptibility and 
resistance rates of P. aeruginosa to imipenem in USA 
were reported to be 24% and 70%, respectively.
In the present study, all tested isolates of P. aeru­
ginosa were sensitive to meropenem with MIC50 and 
MIC90 of 2 and 2 µg/ml. Contrary to the present results, 
a study in Egypt reported a resistance rate of 37.7% to 
meropenem among P. aeruginosa isolated from hospi-
talized cancer patients (Decousser et al., 2003). This is 
explained by the differences in the pattern of antibiotic 
prescription and usage between the two studies. The 
susceptibility rate to meropenem in clinical isolates of 
P. aeruginosa in a study in Spain was 92.98% from 2005 
to 2010 (Casal et al., 2012).
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According to our findings, the susceptibility rate of 
ticarcillin was found to be 80.1%. Similarly, the sus-
ceptibility rate to ticarcillin was reported to be 81% in 
a study in France (Decousser et al., 2003). The resist-
ance rate of P. aeruginosa in the present study to ticar-
cillin was found to be 19.9% which was much lower 
than the resistance rate reported in a study in Egypt, 
where the resistance rate of P. aeruginosa isolated from 
hospitalized cancer patients to ticarciilin was found to 
be 91.7% (Ashour and El-Sharif, 2009) which is much 
higher than the resistance rate in the present study 
which was found to be 19.9%. 
All P. aeruginosa isolates, in the present study, were 
susceptible to piperacillin with MIC50 and MIC90 of 
8 and 32 µg/ml, respectively. On the other hand, only 
53% of 303 clinical isolates of P. aeruginosa collected 
from patients in five hospitals in the greater Cairo 
region between July 1999 and June 2000, were suscep-
tible to piperacillin (El Kholy et al., 2003).
In line with the literature (Landman et al., 2008), 
the present data revealed that polymyxin B had in 
vitro activity against the isolates tested, with suscep-
tibility rates of 100% for P. aeruginosa. In contrast to 
the present findings recent studies showed resistance 
of P. aeruginosa to polymyxin  B. While P. aeruginosa 
are typically susceptible to polymyxins, resistance has 
been known to occur as polymyxin usage increases, 
the emergence of resistance to this agent of last resort 
becomes an obvious concern (Landman et al., 2005).
All P. aeruginosa isolates in the present study were 
susceptible to amikacin with MIC50 and MIC90 of 8 and 
8 µg/ml, respectively. In agreement with the current 
amikacin susceptibility results were data in studies in 
Turkey where the susceptibility rate of P. aeruginosa 
strains to amikacin was 100% (Gerçeker and Gürler, 
1995) and in Jamaica (Brown and Izundu, 2004).
To determine the possible mechanisms of resist-
ance of P. aeruginosa isolates to antibiotics, the iso-
lates were tested for β-lactamase production and efflux 
pumps-mediated resistance. P. aeru ginosa is known to 
possess β-lactamase-mediated resistance to antibiotics 
(Walsh, 2010). In the present study, 48.8% of isolates 
showed β-lactamase production activity. The reduction 
in MICs of ticarcillin, aztreaonam, and meropenem 
in the presence of an efflux pump inhibitors (DNP or 
DCCD) suggested the contribution of an efflux-medi-
ated mechanism in tested P. aeruginosa isolates to dif-
ferent antibiotics. This finding was consistent to other 
reports which showed a major contribution of efflux 
as the major resistance mechanism in P. aeruginosa 
(Drissi et al., 2008). 
The possible mechanisms of low-level imipenem 
resistance in the imipenem resistant isolate were inves-
tigated. First, the effect of EDTA on the zone of inhi-
bition by imipenem disc was performed. The addition 
of EDTA increased the inhibition zone from 11 mm 
to 21 mm, which might suggest a MβL-mediated 
imipenem resistance (Jesudason et al., 2005). Therefore, 
PCR analysis of the isolate was performed to detect 
IMP and VIM MβLs, which was supported by the full 
sensitivity of the isolate to meropenem. Although, the 
present PCR results excluded the presence of the pres-
ence of the aforementioned metallo-β-lactamase genes, 
several types of MBL enzymes including IMP-type, 
VIM-type, SPM-1, GIM-1, SIM-1 – have been reported 
in P. aeruginosa (Queenan and Bush, 2007). In the pre-
sent study, imipenem resistance may be explained by 
the presence of efflux pump-mediated mechanism 
using the constitutively expressed MexAB-OprM efflux 
system which extrudes most β-lactams in its broad sub-
strate spectrum including imipenem (Quale et al., 2006) 
and the MexEF-OprN system although not contribute 
to β-lactam efflux, its overexpression indirectly affects 
the efficacy of carbapenems through a  concomitant 
reduction of the carbapenem-specific OprD porin 
protein (Rodriguez-Martinez et al., 2009). Another 
possibility is the overproduction of chromosomal 
AmpC β-lactamase as shown in the spectrophotometric 
hydrolysis of imipenem. The inducible effect of some 
β-lactamases slowly hydrolyses imipenem as shown in 
several studies which demonstrated the role of cephalo-
sporinase in imipenem resistance among P. aeruginosa 
(Farra et al., 2008).
Other mechanisms of carbapenem resistance have 
been identified such as class Clavulanic acid inhibi-
ted ESBLs with hydrolytic activity that encompasses 
imipenem such as GES-2 (Poirel et al., 2001). Thus, 
imipenem resistance in the present study is probably 
due to several interplay mechanisms including AmpC 
overproduction, efflux pumps, and loss of OprD rather 
than due to the production of specific MBLs, although 
a novel MBLs may be involved (Shehabi et al., 2011). 
In agreement to the present study, P. aeruginosa iso-
lates were reported negative to blaVIM1a,b and blaIMP1,2 
genes, however isolates were found positive to class 1 
integrons (Kouda et al., 2009). Contrary to the absence 
of integron mediated MBLs in the present study, class 
1 integron containing MBL-mediated resistance was 
reported elsewhere (Tawfik et al., 2012). P. aeruginosa 
can very often accumulate different resistance mecha-
nisms leading to increased resistance to carbapenems 
as well as other antimicrobial agents (Farra et al., 2008). 
ESBLs were reported in P. aeruginosa isolates (Stra-
teva and Yordanov, 2009) and ESBLs and MBLs were 
detected at high prevalence rate in neighbouring regions 
(Woodford et al., 2008). In addition, ESBLs are on the 
rise globally as resistant determinants among P. aerugi­
nosa isolates (Livermore, 2002). A possible resistance 
mechanism of these isolates could be due to the loss 
of porin (OprD) (Quale et al., 2006). The discrepancy 
El Zowalaty M.E. and Gyetvai B. 130
between the results of the EDTA-disc diffusion syn-
ergy test, spectrophotometric assay of imipenem and 
the PCR might be explained by the presence of carba-
penemases other than IMP- or VIM-type MBLs. This 
is consistent with the other findings that in the absence 
of specific carbapenemases, the mechanisms leading to 
carbapenem resistance are usually multifactorial and 
it has been recently implicated to involve the interplay 
among various contributory factors as augmented anti-
biotic extrusion efflux pumps, increased chromosomal 
cephalosporinase or AmpC activity, and reduced OprD 
porin expressions (Rodriguez-Martinez et al., 2009).
In summary, the results of the present study dem-
onstrate the effectiveness of carbapenems against the 
problematic P. aeruginosa. Independent on the geo-
graphical location, meropenem, piperacillin, amika-
cin, polymyxin B, and imipenem were the most active 
agents against P. aeruginosa. Monotherapy with poly-
myxin B may be adequate to control P. aeru ginosa infec-
tions. Although data presented in this study revealed 
that no resistance of clinical isolates of P. aeruginosa 
against piperacillin, meropenem, polymyxin  B, and 
amikacin was detected, the importance of the results is 
indicating that escalating rates of MDR among isolates 
still pose a clinical problem for patients and health offi-
cials. The prevalence of multi-drug-resistant P. aerugi­
nosa (MDR-PA) in many parts of the world is concern-
ing and will jeopardize the current antimicrobial agents 
because efficacious antimicrobial therapeutic options 
are limited (Song, 2008). 
Conclusions. One of the major scientific concerns 
in the medical community is that the antibiotic clini-
cal protocol for the treatment of bacterial infections 
in private and governmental clinics and hospitals in 
developing countries is inappropriate. Antibiotics are 
prescribed without prior recommendation and knowl-
edge of the in vitro antimicrobial susceptibility testing. 
In addition, over-the-counter (OTC) antimicrobial 
prescription among pharmacists and self-antibiotic 
medication among the public is a present ongoing phe-
nomenon. The patterns of antibiotic usage in develop-
ing countries such as overuse, underuse, or inadequate 
dosing contribute to a great extent to the emergence 
of antimicrobial resistance in Gram negative bacteria 
(Barbosa and Levy, 2000; Essack et al., 2008). 
The misuse of antibiotics will contribute to the 
failure of treatment as well as the emergence of new 
resistant bacterial strains. Furthermore, the present 
study highlights the importance of improvement or 
amendment of antibiotic drug policies and anti biotic 
stewardship in developing countries as well as globally 
(Essack et al., 2008). In addition, this alarming trend of 
resistance deserves attention and concern among health 
care providers and requires the continuation of antimi-
crobial surveillance studies worldwide and reduction in 
antibiotic use to control antibiotic resistance (Hamil-
ton-Miller, 2004). Furthermore, search for new antimi-
crobial agents including nanoantimicrobial antibiotics 
and alternative therapeutic agents will help control the 
challenging and spreading resistance of P. aeru ginosa to 
antimicrobial agents.
In developing countries, high proportion of patients 
in hospital and outpatient clinics receive antibiotic with-
out prescription and the inappro priate antibiotic may 
be prescribed without prior antimicrobial sensitivity 
testing as well. One more issue is that, little data about 
the endemic antimicrobial resistance is available from 
developing countries, where over-the-counter antibiotic 
usage is a common phenomenon. Further studies are 
recommended to thorouglhy understand the different 
resistance machanisms, interactions among bacteria 
as well as to continue global surveillance studies to 
monitor the emerging resistance trends. This will help 
find appropriate and effective measures to restore the 
balance of coexistence between humans and bacteria. 
We are currently investigating antimicrobial resistance 
among zoonotic P. aeru ginosa isolates.
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